iVIEW is developing a safe, non-toxic and long-acting Povidone Iodine nasal spray for the prevention and treatment of COVID-19 infection to curb the COVID-19 spread

[April 5, 2020] Doylestown, Pennsylvania – IVIEW Therapeutics Inc., an innovative clinical stage specialty pharmaceutical company that is committed to becoming a leader in topical drug development with specialization in ophthalmology is currently developing treatment and prevention strategies against the novel SARS-CoV-2, also known as, COVID-19.[…]

iView Announces First Patient Treated in Phase 2 Clinical Trial Program Evaluating IVIEW-1201 in Patients with Acute Adenoviral Conjunctivitis

[December 19, 2019] Doylestown, Pennsylvania — iView Therapeutics Inc. today announced that the first patient has been treated in the Phase 2 IVIEW-1201-01-AIC clinical trial program accessing the efficacy of IVIEW-1201 for adolescent and adult patients (age ≥15 years) with Acute Adenoviral Conjunctivitis. First subject was dosed on 19 Dec in India at Disha Eye Hospital Pvt. Ltd. Kolkata under this Phase II Clinical trial program. This study is planned in US, India and China simultaneously.[…]

iVIEW-1201 Phase II IND clinical trial application for the Treatment of Adenoviral Conjunctivitis approved by Indian Regulatory Authority (CDSCO)

[June 6, 2019] Doylestown, Pennsylvania–iVIEW Therapeutics Inc., an innovative specialty pharmaceutical company committed to becoming a leader in topical drug development with specialization focus on ophthalmology, today announced that its Phase II clinical trial IND application of iVIEW-1201 for the Treatment of Adenoviral Conjunctivitis has been approved by Indian Regulatory Authority, CDSCO.[…]

iVIEW Therapeutics was awarded SBIR Innovative Year 2 Grant by NIH’s National Institute of Allergy and Infectious Diseases (NIAID)

[April 11, 2019] Doylestown, Pennsylvania–iVIEW Therapeutics Inc., a clinical-stage biotechnology company focusing on topical drug development on the areas of ophthalmology, otolaryngology, and dermatology, today announced that it has been awarded a Small Business Innovation Research (SBIR) Year 2 Award of $300,000 from National Institute of Allergy and Infectious Diseases (NIAID) at National[…]

iVIEW-1201 Phase II IND application for the Treatment of Adenoviral Conjunctivitis Accepted by US FDA

[December 31, 2018] Doylestown, Pennsylvania–iVIEW Therapeutics Inc., an innovative specialty pharmaceutical company committed to becoming a leader in topical drug development with specialization focus on ophthalmology, dermatology and otolaryngology, today announced that its Phase II clinical trial IND application of iVIEW-1201 was been accepted by US FDA. As Dr. Wendy Streight, FDA Regulatory Project Manager, said in her[…]

iVIEW Therapeutics Closes its A round financing to move forward iVIEW-1201, a novel sustain release povidone iodine gel forming solution, into phase II clinical trials for the treatment of adenoviral conjunctivitis

[June 27, 2018] Doylestown, Pennsylvania–iVIEW Therapeutics Inc., an innovative specialty pharmaceutical company committed to becoming a leader in topical drug development with specialization focus on ophthalmology, dermatology and otolaryngology, today announced that it has closed its A round financing of close to $6 million dollars from both strategic and[…]